Immunotherapy through immune checkpoint inhibition by blocking the PD-1/PD-L1 signaling pathway that enhances anti-cancer T cell immunity has shown promising and significant efficacy in a variety of malignancies, including LC [44,45,46,47]. The gene discussed is CD274; the disease is laryngotracheoesophageal cleft.